Drug intelligence / Profile preview

r-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + peptides from hpv-16 e6 and e7

Development stage: Preclinical
Modality: Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous, Intradermal, Intravenous

Overview

This is a combination investigational therapeutic composed of the r-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride (a cationic lipid commonly used for nanoparticle or liposome-based delivery) and synthetic peptides derived from the E6 and E7 oncoproteins of human papillomavirus type 16 (HPV-16). The E6 and E7 proteins are key drivers in HPV-mediated oncogenesis by promoting degradation of tumor suppressor p53 (E6) and cell cycle dysregulation (E7)[1][4][8]. Peptides derived from these proteins are used as antigens to stimulate cytotoxic T lymphocyte responses against HPV-infected or transformed cells[2][4][5][8]. The cationic lipid component likely serves as a delivery vehicle to enhance cellular uptake or immunogenicity. This combination is being explored primarily as a therapeutic vaccine candidate for cervical cancer prevention or treatment by inducing targeted immune responses against HPV-transformed cells[4][5].

Other names: r-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + peptides from hpv-16 e6 and e7

Targets

HPV16 E6 oncoprotein

Beyond the preview

Go deeper on r-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + peptides from hpv-16 e6 and e7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on r-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + peptides from hpv-16 e6 and e7.

Explore the full profile